KP-10614

KP-10614 is a potent, orally active platelet aggregation inhibitor. KP-10614 inhibits platelet aggregation induced by ADP with IC50 of 1 nM. KP-10614 causes dose-dependent inhibition of ex vivo platelet aggregation in rats. KP-10614 shows antithrombotic effects in various thrombosis models. KP-10614 can be used for thrombotic diseases research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

  • CAS. Nr.: 130273-99-3
  • Formel: C23H32O4
  • Molecular Weight:372.50
  • Speicherung:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Biologische Aktivität
  • Chemical Information
  • Reinheit & Dokumentation
  • Verweise
  • Help & FAQs
MOQ
Minimum order quantity
100 mg

Angebot einholen Auf Lager

Other size
Angebot einholen
Please select quantity
Amount: USD 0.00